Arterial Elasticity: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)
Status
Conditions
Details and patient eligibility
About
The purpose of this study is to find out if starting anti-retroviral therapy (ART) above 500 cluster-of-differentiation-4 (CD4)+ cells/milliliter (mL) ('early ART group') is better at reducing the stiffness of arteries than waiting to start ART until the CD4+ drops below 350 cells/mL ('deferred ART group'). Artery stiffness has been associated with an increased risk of cardiovascular (heart) disease, and could be useful as an earlier indicator of heart disease. In this study, the stiffness of arteries will be measured at study entry, months 4, 8, 12, and annually thereafter, using a tonometer on the participant's forearm.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Simultaneous co-enrollment in the START study
- Signed informed consent
Exclusion criteria
- Inability to ascertain waveform measurements that can be analyzed, i.e. atrial fibrillation
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal